Dana-Farber Brigham Cancer Center research shows blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence (IMAGE)

Dana-Farber Cancer Institute

Dana-Farber Brigham Cancer Center research shows blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence

Caption

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

Kindly courtesy Dana-Farber Cancer Institute

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.